5.2.5. blood urine biomarkers. urine serum biomarkers well tissue-based biomarkers proposed improving detection risk stratification pca patients, potentially avoiding unnecessary biopsies. however, studies necessary validate efficacy . 5.2.5.1. blood based biomarkers: phi/4k score/isopsa/stockholm3/proclarix use biomarkers (included nomogram) may help predicting indolent pca . several assays measuring panel kallikreins serum plasma commercially available, including u.s. food drug administration (fda) approved prostate health index (phi) test (combining free total psa [-2]pro-psa isoform [p2psa]), four kallikrein (4k) score test (measuring free, intact total psa kallikrein-like peptidase 2 [hk2] addition parameters age, dre prior biopsy status). tests intended reduce number unnecessary prostate biopsies psa-tested men. prospective multi-centre studies demonstrated phi 4k score test out-performed f/t psa pca detection, improved prediction cspca men psa 2–10 ng/ml . head-to-head comparison tests performed equally . contrast 4k score phi, focus concentration psa isoforms, isopsa utilises technology focuses structure psa. multi-centre prospective validation 271 men assay area curve (auc) 0.784 high-grade vs. low-grade cancer/benign histology, superior aucs total psa percent free psa . men negative mpmri, psa-d, 4k score family history predicted risk cspca biopsy using nomogram reduced number negative biopsies indolent cancers 47% 15%, respectively, missing 10% cspca . stockholm3 test prediction model based several clinical variables (age, first-degree family history pca, previous biopsy), blood biomarkers (total psa, free psa, ratio free psa total psa, human kallikrein 2, macrophage inhibitory cytokine-1, microseminoprotein-β ), polygenic risk score predicting risk pca isup grade group ≥ 2, shown reduce percent clinically insignificant cancers used combination mri psa screening population . also potential decrease number mpmri scans required prostate cancer screening . proclarix® test blood-based test estimates likelihood cspca according measurement results thrombospondin-1, cathepsin d, total psa, percentage free psa patient age. test correlated detection significant pca, notably case equivocal mri (pi-rads 3 lesions) . 5.2.5.2. urine biomarkers: pca3/selectmdx/mi prostate score (mips)/exodx prostate cancer gene 3 (pca3) overexpressed long non-coding rna (lncrna) biomarker detectable urine sediments obtained three strokes prostatic massage dre. however, clinical utility commercially available progensa urine test pca3 biopsy decision-making remains uncertain. still, combining mri findings pca3 score may improve risk stratification . selectmdx test similarly based mrna biomarker isolation urine. presence hoxc6 dlx1 mrna levels assessed provide estimate risk presence pca biopsy well presence high-risk cancer . multi-centre trial evaluated selectmdx men mri pi-rads score < 4 pi-rads score < 3, percentage missed cspcas 6.5% 3.2%, respectively, whereas 45.8% 40% biopsies avoided . hendriks et al., found biopsies avoided high-grade pcas detected mri-based biopsy strategy compared selectmdx strategy. tests combined, gleason grade > 1 lesions found, number negative low-grade cancer biopsies doubled . combining selectmdx mri men psa 3–10 ng/ml negative predictive value (npv) 93% . clinically added value selectmdx era upfront mri targeted biopsies remains unclear . tmprss2-erg fusion, fusion trans-membrane protease serine 2 (tmprss2) erg gene detected 50% pcas . detection tmprss2-erg urine added pca3 expression serum psa (mi(chigan)prostate score [mips]), cancer prediction improved . exosomes secreted cancer cells may contain mrna diagnostic high-grade pca . use exodx prostate intelliscore urine exosome assay resulted avoiding 27% unnecessary biopsies compared standard care (soc). however, currently, mips-score exodx assay considered investigational. screening population erspc study use pca3 4k panel added risk calculator led improvement auc less 0.03 . based available evidence, biomarkers could help discriminating aggressive non-aggressive tumours additional value compared prognostic parameters currently used clinicians . however, upfront mri also likely affect utility above-mentioned biomarkers (see section 5.2.3.2).